Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Clinical trial data from the SURMOUNT and SURPASS programs showed tirzepatide patients losing an average of 20 to 25 percent of body weight at the highest doses, compared to roughly 15 to 17 percent for semaglutide in similar trials
Cureus 16(9):e69453
BPC-157 is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications
Results can vary depending on the condition being addressed and the consistency of the protocol
The duration of protocols in studies varies from a few days to several weeks
These protocols form the foundation for current therapeutic dosing recommendations
US$ 25.48
US$ 25.82
US$ 23.86
US$ 22.85
US$ 28.03
